<DOC>
	<DOC>NCT00051844</DOC>
	<brief_summary>This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.</brief_summary>
	<brief_title>Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Male or female at least 18 years old HIV RNA level &gt;1000 copies/mL at screening CD4 &gt;50 cells/uL at screening Patient is currently taking a regimen that includes an NNRTI plus 2 NRTIs for at least 28 days and is currently failing this regimen Patient has adequate hematology tests (absolute neutrophil count &gt;1000/uL, Platelets&gt;75,000uL, hemoglobin 9g/L) Patient has adequate renal function (serum creatinine of &lt;1.5 upper limit of normal) Patient has adequate liver function (AST, ALT, and bilirubin &lt; 2.5 upper limit of normal) Previous use of protease inhibitors (except if patient has short duration of PI and was switched for tolerability reasons when viral load was &lt;50 copies) This exception does not include Viracept Women who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>HIV</keyword>
	<keyword>NNRTI Failure</keyword>
	<keyword>HIV Infections</keyword>
</DOC>